Diaceutics Past Earnings Performance
Past criteria checks 0/6
Diaceutics's earnings have been declining at an average annual rate of -56.5%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 16.4% per year.
Key information
-56.5%
Earnings growth rate
-56.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 16.4% |
| Return on equity | -7.3% |
| Net Margin | -10.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Diaceutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 26 | -3 | 26 | 0 |
| 31 Mar 24 | 25 | -2 | 25 | 0 |
| 31 Dec 23 | 24 | -2 | 23 | 0 |
| 30 Sep 23 | 23 | -1 | 21 | 0 |
| 30 Jun 23 | 22 | 0 | 20 | 0 |
| 31 Mar 23 | 21 | 0 | 18 | 0 |
| 31 Dec 22 | 20 | 1 | 16 | 0 |
| 30 Sep 22 | 18 | 0 | 15 | 0 |
| 30 Jun 22 | 16 | 0 | 14 | 0 |
| 31 Mar 22 | 15 | 0 | 13 | 0 |
| 31 Dec 21 | 14 | 1 | 12 | 0 |
| 30 Sep 21 | 14 | 0 | 12 | 0 |
| 30 Jun 21 | 13 | -1 | 11 | 0 |
| 31 Mar 21 | 13 | 0 | 11 | 0 |
| 31 Dec 20 | 13 | 0 | 10 | 0 |
| 30 Sep 20 | 14 | 2 | 9 | 0 |
| 30 Jun 20 | 14 | 3 | 9 | 0 |
| 31 Mar 20 | 14 | 2 | 9 | 0 |
| 31 Dec 19 | 13 | 0 | 8 | 0 |
| 30 Sep 19 | 12 | 0 | 7 | 0 |
| 30 Jun 19 | 11 | 0 | 6 | 0 |
| 31 Mar 19 | 11 | 0 | 6 | 0 |
| 31 Dec 18 | 10 | 1 | 6 | 0 |
| 31 Dec 17 | 7 | 1 | 4 | 0 |
| 31 Dec 16 | 5 | 1 | 2 | 0 |
| 31 Dec 15 | 1 | 0 | 1 | 0 |
Quality Earnings: 7DC is currently unprofitable.
Growing Profit Margin: 7DC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7DC is unprofitable, and losses have increased over the past 5 years at a rate of 56.5% per year.
Accelerating Growth: Unable to compare 7DC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7DC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 7DC has a negative Return on Equity (-7.34%), as it is currently unprofitable.